Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.
about
The safety of pharmacologic options for the treatment of persons with hemophilia.Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.European principles of inhibitor management in patients with haemophilia.
P2860
Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tailoring hemostatic therapies ...... ents with severe hemophilia A.
@en
type
label
Tailoring hemostatic therapies ...... ents with severe hemophilia A.
@en
prefLabel
Tailoring hemostatic therapies ...... ents with severe hemophilia A.
@en
P2093
P2860
P356
P1476
Tailoring hemostatic therapies ...... ents with severe hemophilia A.
@en
P2093
M E Mancuso
M Franchini
P M Mannucci
P2860
P304
P356
10.1111/JTH.13356
P577
2016-05-07T00:00:00Z